(Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -12.81%31.26B | -9.45%18.81B | 24.08%67.54B | 29.14%50.84B | 29.68%35.86B | 23.76%20.77B | -19.57%54.43B | -20.47%39.36B | --27.65B | -7.45%16.78B |
Operating income | -12.81%31.26B | -9.45%18.81B | 24.08%67.54B | 29.14%50.84B | 29.68%35.86B | 23.76%20.77B | -19.57%54.43B | -20.47%39.36B | 27.65B | -7.45%16.78B |
Cost of sales | 16.26%-21.02B | ---- | -17.98%-46.69B | ---- | -36.19%-25.1B | ---- | 12.80%-39.57B | ---- | ---18.43B | ---- |
Operating expenses | 16.26%-21.02B | 14.94%-12.54B | -17.98%-46.69B | -28.15%-34.7B | -36.19%-25.1B | -33.14%-14.75B | 12.80%-39.57B | 14.49%-27.08B | -18.43B | -0.87%-11.08B |
Gross profit | -4.76%10.24B | 4.00%6.26B | 40.33%20.85B | 31.33%16.14B | 16.67%10.75B | 5.56%6.02B | -33.34%14.86B | -31.10%12.29B | 9.22B | -20.22%5.71B |
Selling expenses | -3.41%-5.22B | -17.90%-2.41B | -117.13%-10.74B | -162.28%-6.94B | -105.08%-5.05B | -40.14%-2.05B | 8.52%-4.95B | 17.69%-2.65B | ---2.46B | 34.55%-1.46B |
Administrative expenses | 7.67%-1.12B | -6.54%-475.64M | -1.10%-2.6B | -15.74%-1.54B | -13.51%-1.22B | -3.58%-446.46M | 5.16%-2.57B | 16.25%-1.33B | ---1.07B | 18.88%-431.04M |
Research and development expenses | -9.82%-906K | 49.22%-355K | -49.69%-58.42M | ---9.78M | ---825K | ---699.06K | ---39.03M | ---- | ---- | ---- |
Profit from asset sales | ---- | -673.05%-1.52M | ---- | -53.02%1.09M | ---- | -123.95%-196.59K | ---- | --2.31M | ---- | --820.78K |
Impairment and provision | -40.27%2.25M | -5.16%-147.19M | -64.00%2.58M | -44.35%-473.95M | -50.38%3.76M | -407.71%-139.97M | 130.70%7.16M | -9,834.61%-328.34M | --7.58M | 1,811.40%45.49M |
-Other impairment is provision | -40.27%2.25M | -5.16%-147.19M | -64.00%2.58M | -44.35%-473.95M | -50.38%3.76M | -407.71%-139.97M | 130.70%7.16M | -9,834.61%-328.34M | --7.58M | 1,811.40%45.49M |
Special items of operating profit | 16.97%744.89M | 29.38%22.76M | 255.24%1.49B | -72.08%68.58M | 290.58%636.84M | -65.32%17.59M | -46.58%420.08M | -52.36%245.63M | ---334.17M | -64.76%50.73M |
Operating profit | -9.43%4.65B | -2.12%2.78B | 15.75%8.95B | -17.91%5.99B | -4.24%5.13B | -16.92%2.84B | -48.25%7.73B | -46.13%7.3B | 5.36B | -24.44%3.42B |
Financing cost | 39.26%-97.9M | -59.74%124.94M | -53.41%-297.89M | 193.04%581.83M | -45.13%-161.2M | 289.80%310.32M | 12.48%-194.18M | -288.60%-625.37M | ---111.07M | 251.89%79.61M |
Share of profits of associates | 3.43%24.85M | ---- | -33.58%109.56M | ---- | -73.36%24.03M | ---- | -0.04%164.94M | ---- | --90.2M | ---- |
Share of profit from joint venture company | -224.44%-2M | ---- | -396.41%-12.17M | ---- | 140.24%1.6M | ---- | 8.72%-2.45M | ---- | ---3.99M | ---- |
Special items of earning before tax | ---- | -45.34%1.19M | ---- | 123.46%1.99M | ---- | 52.47%2.17M | ---- | ---8.49M | ---- | --1.42M |
Earning before tax | -8.48%4.57B | -7.81%2.91B | 13.62%8.75B | -1.34%6.57B | -6.33%5B | -9.93%3.16B | -48.25%7.7B | -50.58%6.66B | 5.33B | -21.88%3.5B |
Tax | -5.41%-906.37M | 31.26%-474.32M | 1.92%-1.4B | -0.77%-1.15B | -9.89%-859.9M | -17.52%-690.06M | 41.44%-1.43B | 49.55%-1.14B | ---782.48M | 44.46%-587.18M |
After-tax profit from continuing operations | -11.36%3.67B | -1.25%2.44B | 17.16%7.35B | -1.78%5.42B | -9.12%4.14B | -15.45%2.47B | -49.59%6.27B | -50.79%5.52B | 4.55B | -14.91%2.92B |
Earning after tax | -11.36%3.67B | -1.25%2.44B | 17.16%7.35B | -1.78%5.42B | -9.12%4.14B | -15.45%2.47B | -49.59%6.27B | -50.79%5.52B | 4.55B | -14.91%2.92B |
Minority profit | 57.55%361M | -22.06%128.75M | -51.82%557.91M | -75.71%216.93M | -60.46%229.13M | -53.22%165.2M | -57.35%1.16B | -66.62%893.09M | --579.46M | -36.74%353.15M |
Profit attributable to shareholders | -15.40%3.31B | 0.25%2.31B | 32.77%6.79B | 12.49%5.21B | -1.63%3.91B | -10.25%2.3B | -47.42%5.11B | -45.83%4.63B | 3.97B | -10.66%2.56B |
Basic earnings per share | -15.40%1.5978 | -15.09%1.1148 | 27.72%3.282 | 6.79%2.5165 | -7.17%1.8887 | 0.00%1.3129 | -48.42%2.5697 | -46.15%2.3566 | 2.0345 | -10.66%1.3129 |
Diluted earnings per share | -15.40%1.5978 | -15.09%1.1148 | 27.72%3.282 | 6.79%2.5165 | -7.17%1.8887 | 0.00%1.3129 | -48.42%2.5697 | -46.15%2.3566 | 2.0345 | -10.66%1.3129 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) |
Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
Auditor | -- | -- | Ernst & Young (Special General Partnership), Ernst & Young | -- | -- | -- | KPMG | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data
No Data